MAXALT

LOE Approaching

rizatriptan benzoate

NDAORALTABLET
Approved
Jun 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
85

Mechanism of Action

5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Clinical Trials (5)

NCT06960655N/AEnrolling By Invitation

Improving Lipid Optimization Quality and Treatment Options in ASCVD

Started Oct 2025
300 enrolled
HypercholesterolemiaASCVD
NCT06863272Phase 1/2Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Started Jul 2025
360 enrolled
Castration-Resistant Prostatic CancerMetastasis
NCT06342115Phase 4Recruiting

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

Started Mar 2025
176 enrolled
Febrile Neutropenia
NCT06402383N/AActive Not Recruiting

Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living with HIV

Started May 2024
2,000 enrolled
Cervical Cancer
NCT06136624Phase 3Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Started Dec 2023
1,310 enrolled
Prostate Cancer Metastatic